Fig. 4: DP2 antagonism or DP1 agonism attenuates RV-induced type-2 inflammation and promotes type-1 immunity.
Mice with CEA were inoculated with RV-1b and treated daily with a DP2 antagonist, a DP1 agonist, or vehicle starting from day 99. Mice were euthanized at 1, 3 and 7 dpi. A Number of neutrophils (SigF−CD11b+Ly6G+CD11c−) and eosinophils (SigF+CD11b+Ly6G−CD11c−) in the lungs. B Number of TH2 cells (GATA3+CD4+T) and ILC2s (CD3ε−CD19−CD45R−CD11c−Gr‐1−CD11b−NK1.1− CD90.2+CD200R1+ GATA3+) in the lungs. C IL-4 and IL-5 concentration in the bronchoalveolar lavage fluid (BALF). D IL-17A expression in the BALF. E IFN-γ expression in the BALF and TNF expression in the lung. A–E Data are presented as mean ± SEM and are representative of two independent experiments showing similar results (n = 4–11 mice per group). Statistical significance between different time points or different groups was determined using one-way ANOVA with Dunnett’s multiple comparison test. * denotes p < 0.05; ** denotes p < 0.01 and *** denotes p < 0.001 compared to Vehicle group. # denotes p < 0.05, ## denotes p < 0.01 and ### denotes p < 0.001 compared to RV-infected group at corresponding time point. F RV-1b infected mice were treated with vehicle or DP2 antagonist (OC000459) or DP1 antagonist (MK0524) or both DP2 and DP1 antagonist daily from day 99 and euthanized at 7 dpi. Concentrations of IFN-γ in the BALF and TNF in the lung. G RV-1b infected mice were treated with vehicle, DP2 antagonist, fluticasone, or both DP2 antagonist and fluticasone daily from day 99 and euthanized at 7 dpi. Concentrations of IFN-γ in the BALF and TNF in the lung. F, G Data are presented as box-and-whisker plots showing individual data points with the boxes representing quartiles and whiskers indicating the range and are representative of two independent experiments showing similar results (n = 5–7 mice per group). * denotes p < 0.05 and ** denotes p < 0.01 compared to vehicle group. δ denotes p < 0.05, δδ denotes p < 0.01 and δδδ denotes p < 0.001 compared to DP2 antagonist treated group. Source data are provided as a Source Data file.
